Literature DB >> 2373185

The effect of prostaglandin F2 alpha on trabecular outflow facility in cynomolgus monkeys.

B T Gabelt1, P L Kaufman.   

Abstract

Cynomolgus monkeys were treated topically in one eye with 2 micrograms of prostaglandin F2 alpha -l-isopropylester (PGF2 alpha-IE) twice daily. On day 4, 3 hr after the seventh dose, intraocular pressure (IOP) was 8.1 +/- 0.7 mmHg lower in the treated than in the control eyes. On day 5, after the ninth PGF2 alpha dose, gross facility was measured in both eyes by determining the rate of fluid flow from an external reservoir into the eye at two different IOP levels. Simultaneously, trabecular facility was measured by determining the rate of accumulation of intracamerally infused radioiodinated albumin in the general circulation. Gross facility was 40-60% higher in PGF2 alpha treated than in control eyes, but there was no difference in trabecular facility. The increase in gross facility sometimes reported following PGF2 alpha probably represents increased pseudofacility or uveoscleral facility, rather than true facility of outflow through the trabecular meshwork and Schlemm's canal.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2373185     DOI: 10.1016/0014-4835(90)90174-s

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  19 in total

1.  Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure.

Authors:  M Kimal Arici; A Topalkara; C Güler
Journal:  Int Ophthalmol       Date:  1998       Impact factor: 2.031

2.  The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%.

Authors:  M Diestelhorst; S Roters; G K Krieglstein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-01       Impact factor: 3.117

Review 3.  Toward in vivo two-photon analysis of mouse aqueous outflow structure and function.

Authors:  Jose M Gonzalez; Minhee K Ko; Andrius Masedunskas; Young-Kwon Hong; Roberto Weigert; James C H Tan
Journal:  Exp Eye Res       Date:  2016-05-12       Impact factor: 3.467

4.  Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys.

Authors:  B'Ann True Gabelt; Elizabeth A Hennes; Mark A Bendel; Chase E Constant; Mehmet Okka; Paul L Kaufman
Journal:  J Ocul Pharmacol Ther       Date:  2009-02       Impact factor: 2.671

Review 5.  Prospects for lentiviral vector mediated prostaglandin F synthase gene delivery in monkey eyes in vivo.

Authors:  Eun Suk Lee; Carol A Rasmussen; Mark S Filla; Sarah R Slauson; Aaron W Kolb; Donna M Peters; Paul L Kaufman; B'Ann T Gabelt; Curtis R Brandt
Journal:  Curr Eye Res       Date:  2014-02-21       Impact factor: 2.424

Review 6.  Pharmacological advances in the treatment of glaucoma.

Authors:  J B Serle
Journal:  Drugs Aging       Date:  1994-09       Impact factor: 3.923

7.  Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study.

Authors:  K Sheng Lim; Cherie B Nau; Megan M O'Byrne; David O Hodge; Carol B Toris; Jay W McLaren; Douglas H Johnson
Journal:  Ophthalmology       Date:  2008-05       Impact factor: 12.079

8.  Latanoprost-induced changes in rat intraocular pressure: direct or indirect?

Authors:  Shahid Husain; Phillip W Yates; Craig E Crosson
Journal:  J Ocul Pharmacol Ther       Date:  2008-08       Impact factor: 2.671

9.  The influence of Latanoprost 0.005% on aqueous humor flow and outflow facility in glaucoma patients: a double-masked placebo-controlled clinical study.

Authors:  Sven Dinslage; Arno Hueber; Michael Diestelhorst; Günther Krieglstein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-08       Impact factor: 3.117

10.  Localisation of prostaglandin F2 alpha and E2 binding sites in the human eye.

Authors:  T Matsuo; M S Cynader
Journal:  Br J Ophthalmol       Date:  1992-04       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.